Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Guaiac Fecal Occult Blood Test Compared with Alternative Tests for Patients with Unexplained Anemia or Suspected ColorectalCancer: Comparative Clinical Utility, Cost-Effectiveness, and Evidence-Based Guidelines Guaiac Fecal Occult Blood Test Compared with Alternative Tests for Patients with Unexplained Anemia or Suspected ColorectalCancer: Comparative Clinical Utility, Cost-Effectiveness, and Evidence-Based Guidelines | CADTH.ca Find the information you need Guaiac Fecal Occult Blood Test (...) Compared with Alternative Tests for Patients with Unexplained Anemia or Suspected ColorectalCancer: Comparative Clinical Utility, Cost-Effectiveness, and Evidence-Based Guidelines Guaiac Fecal Occult Blood Test Compared with Alternative Tests for Patients with Unexplained Anemia or Suspected ColorectalCancer: Comparative Clinical Utility, Cost-Effectiveness, and Evidence-Based Guidelines Published on: July 26, 2016 Project Number: RB1006-000 Product Line: Research Type: Other Diagnostics Report Type
Association of adiponectin receptor 1 gene âˆ’Â 106 CÂ >Â T variant with susceptibility to colorectalcancer 27617220 2016 09 12 2018 11 13 2214-5400 9 2016 Sep Meta gene Meta Gene Association of adiponectin receptor 1 gene - 106 C > T variant with susceptibility to colorectalcancer. 210-4 10.1016/j.mgene.2016.07.008 Colorectalcancer (CRC) is the fourth leading cause of cancer-related death around the world and accumulated evidence indicates the association between CRC and obesity and insulin (...) Colorectal Dis. 2010 Feb;25(2):205-12 19888587 Med Mol Morphol. 2007 Jun;40(2):55-67 17572841 ADIPOQ ADIPOR1 Colorectalcancer Gene polymorphism 2016 05 18 2016 07 02 2016 07 11 2016 9 13 6 0 2016 9 13 6 0 2016 9 13 6 1 epublish 27617220 10.1016/j.mgene.2016.07.008 S2214-5400(16)30032-9 PMC5006128
Predictive Value of Carcinoembryonic and Carbohydrate Antigen 19-9 Related to Some Clinical, Endoscopic and Histological ColorectalCancer Characteristics 28356884 2018 11 13 1452-8258 35 3 2016 Sep Journal of medical biochemistry J Med Biochem Predictive Value of Carcinoembryonic and Carbohydrate Antigen 19-9 Related to Some Clinical, Endoscopic and Histological ColorectalCancer Characteristics. 324-332 10.1515/jomb-2016-0014 Colorectalcancer (CRC) is an important oncological and public (...) , School of Medicine. eng Journal Article 2016 07 06 Poland J Med Biochem 101315490 1452-8266 Hybridoma. 1989 Oct;8(5):569-75 2807313 Br J Cancer. 2015 Jul 14;113(2):268-74 26035703 Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53 17932341 PLoS One. 2011;6(5):e20076 21629650 PLoS Med. 2012;9(12):e1001352 23226108 Ann Surg. 1976 Dec;184(6):752-7 999351 Eur J Public Health. 2007 Feb;17(1):80-5 16751634 Colorectal Dis. 2009 Mar;11(3):276-81 18513194 Eur J Cancer. 2010 Mar;46(4):765-81 20116997
Trifluridine-tipiracil (Lonsurf) for refractory metastaticcolorectalcancer Trifluridine-tipiracil (Lonsurf) for refractory metastaticcolorectalcancer Trifluridine-tipiracil (Lonsurf) for refractory metastaticcolorectalcancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Trifluridine-tipiracil (Lonsurf) for refractory metastatic (...) colorectalcancer. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: This report focuses on the use of the trifluridine (TFD) and tipiracil hydrochloride (TPI) combination (Lonsurf; previously called TAS-102) for the treatment of refractory metastaticcolorectalcancer (CRC). TFD is an antineoplastic thymidine-based nucleoside analog that acts as a nucleoside metabolic inhibitor, and TPI is a thymidine phosphorylase inhibitor
Irinotecan-eluting beads (DC Bead, DC Bead M1 and DC Bead Lumi) for liver metastases secondary to colorectalcancer Irinotecan-eluting beads (DC Bead, DC Bead M1 and DC Bead Lumi) for liver metastases secondary to colorectalcancer Irinotecan-eluting beads (DC Bead, DC Bead M1 and DC Bead Lumi) for liver metastases secondary to colorectalcancer NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation NIHR HSRIC. Irinotecan-eluting beads (DC Bead, DC Bead M1 and DC Bead Lumi) for liver metastases secondary to colorectalcancer. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Colorectalcancer is the fourth most common cancer in the UK, accounting for around 12% of all new cases of cancer. In metastaticcolorectalcancer, the tumour has spread beyond the bowel to other parts
Standards and Challenges of Care for ColorectalCancer Today 27493941 2016 08 05 2017 06 01 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Standards and Challenges of Care for ColorectalCancer Today. 156-7 10.1159/000447070 Werner Jens J Department of General, Visceral, Transplantation Surgery, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU), Munich, Germany, Munich, Germany. Heinemann Volker V Department of Internal Medicine III, Klinikum der Universität München (...) , Ludwig-Maximilians-Universität (LMU), Munich, Germany; Comprehensive Cancer Center Munich, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU), Munich, Germany. eng Journal Article 2016 06 16 Switzerland Visc Med 101681546 2297-4725 2016 8 6 6 0 2016 8 6 6 0 2016 8 6 6 1 ppublish 27493941 10.1159/000447070 vis-0032-0156 PMC4945777
Radiotherapy for ColorectalCancer: Current Standards and Future Perspectives 27493944 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Radiotherapy for ColorectalCancer: Current Standards and Future Perspectives. 172-7 10.1159/000446486 Multimodal treatment approaches are indispensable for patients with advanced-stage colorectalcancer. Radiotherapy has been established as essential part of perioperative concepts and was introduced as an option to face challenges (...) such as local relapse or oligometastases. A literature review was performed to summarize evidence and current standards of radiotherapeutic concepts in the treatment of colorectalcancer. For stage II/III rectal cancer, neoadjuvant radiotherapy is superior to adjuvant treatment. Two preoperative regimens have been established and are commonly used with different objectives: short-course radiotherapy (SC-RT) and long-course chemoradiotherapy (LC-CRT). Both reduce the risk of local relapse. Additionally, LC
Diagnostics and Epidemiology of ColorectalCancer 27493942 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Diagnostics and Epidemiology of ColorectalCancer. 158-64 10.1159/000446488 Colorectalcancer is one of the leading causes of cancer-related morbidity and mortality. Main risk factors include advanced age, family history, male sex, and lifestyle factors. Screening can reduce incidence and death from colorectalcancer. Therefore, prevention and early detection (...) are crucial in order to detect and remove pre-neoplastic adenomas and to detect cancers at early stages. Colonoscopy, flexible sigmoidoscopy, and fecal occult blood tests are established tools for screening. Newer fecal immunochemical tests reveal higher sensitivities for advanced adenoma and cancer than guaiac-based hemoccult tests. Molecular stool and blood tests as well as virtual colonoscopy and colon capsule endoscopy are promising new developments so far not established as routine instruments
Screening for ColorectalCancer: US Preventive Services Task Force Recommendation Statement. IMPORTANCE: Colorectalcancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134,000 persons will be diagnosed with the disease, and about 49,000 will die from it. Colorectalcancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectalcancer is 68 years. OBJECTIVE: To update the 2008 US Preventive Services Task (...) Force (USPSTF) recommendation on screening for colorectalcancer. EVIDENCE REVIEW: The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectalcancer or all-cause mortality; the harms of these screening tests
Estimation of Benefits, Burden, and Harms of ColorectalCancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. IMPORTANCE: The US Preventive Services Task Force (USPSTF) is updating its 2008 colorectalcancer (CRC) screening recommendations. OBJECTIVE: To inform the USPSTF by modeling the benefits, burden, and harms of CRC screening strategies; estimating the optimal ages to begin and end screening; and identifying a set of model-recommendable strategies
Genetic Variations in Leptin and Leptin Receptor and Susceptibility to ColorectalCancer and Obesity 27703650 2018 11 13 2008-2398 9 3 2016 Jun Iranian journal of cancer prevention Iran J Cancer Prev Genetic Variations in Lep tin and Lep tin Receptor and Susceptibility to ColorectalCancer and Obesity. e7013 Colorectalcancer (CRC) is the second most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality around the world. With regard to the role of obesity (...) in colorectalcancer (CRC) and the role of lep tin in obesity, we investigated whether leptin ( LEP ) and leptin receptor ( LEPR ) gene variants are associated with CRC risk. We evaluated LEP (rs7799039) and LEPR (rs1137101) gene variants by using PCR-RFLP method in 261 cases with CRC and 339 controls. No significant difference was found for rs7799039 and rs1137101gene variants between the cases with CRC and controls. However, the LEPR rs1137101 "GG" genotype compared with "AA" genotype and "AA + AG
Surgery for ColorectalCancer - Trends, Developments, and Future Perspectives 27493946 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Surgery for ColorectalCancer - Trends, Developments, and Future Perspectives. 184-91 10.1159/000446490 Although colorectal surgery is long established as the mainstay treatment for coloncancer, certain topics regarding technical fine-tuning to increase postsurgical recurrence-free survival have remained a matter of debate throughout (...) the past years. These include complete mesocolic excision (CME), treatment strategies for metastatic disease, significance of hyperthermic intraperitoneal chemotherapy (HIPEC), and surgical techniques for the treatment of colorectalcancer recurrence. In addition, new surgical techniques have been introduced in oncologic colorectal surgery, and their potential to provide sufficiently radical resection has yet to be proven. A structured review of the literature was performed to identify the current
Imaging Procedures for ColorectalCancer 27493943 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Imaging Procedures for ColorectalCancer. 166-71 10.1159/000446143 Radiological imaging plays an important role in the setting of staging, follow-up, and imaging-guided treatment of colorectalcarcinoma (CRC). This review aims to summarize the current state of the art of the different radiological imaging procedures in CRC including an overview over recently published (...) ):1365-71 22271382 Lancet. 2001 Feb 17;357(9255):497-504 11229667 Int J Colorectal Dis. 2001 Sep;16(5):298-304 11686527 Dis Colon Rectum. 2010 Mar;53(3):308-14 20173478 Eur Radiol. 2011 Aug;21(8):1747-63 21455818 Eur J Cancer. 2009 Jan;45(2):228-47 19097774 Acta Radiol. 2007 May;48(4):379-87 17453515 Acad Radiol. 2009 May;16(5):564-71 19345897 Ann Oncol. 2013 Oct;24 Suppl 6:vi81-8 24078665 Br J Surg. 2010 Sep;97(9):1407-15 20564305 J Comput Assist Tomogr. 2007 Nov-Dec;31(6):853-9 18043346 Dis Colon
Minimally Invasive Surgery for the Treatment of ColorectalCancer 27493947 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Minimally Invasive Surgery for the Treatment of ColorectalCancer. 192-8 10.1159/000445815 Reduction in operative trauma along with an improvement in endoscopic access has undoubtedly occupied surgical minds for at least the past 3 decades. It is not at all surprising that minimally invasive colon surgery has come a long way since the first (...) laparoscopic appendectomy by Semm in 1981. It is common knowledge that the recent developments in video and robotic technologies have significantly furthered advancements in laparoscopic and minimally invasive surgery. This has led to the overall acceptance of the treatment of benign colorectal pathology via the endoscopic route. Malignant disease, however, is still primarily treated by conventional approaches. This review article is based on a literature search pertaining to advances in minimally invasive
Physical Activity and Nutrition in Primary and Tertiary Prevention of ColorectalCancer 27493948 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Physical Activity and Nutrition in Primary and Tertiary Prevention of ColorectalCancer. 199-204 10.1159/000446492 Lifestyle factors play a pivotal role in the primary and tertiary prevention of colorectalcancer. The purpose of this review article is to summarize data concerning the effect of the lifestyle factors physical (...) activity (PA) and nutrition in primary and, more importantly, tertiary prevention of colorectalcancer (CRC). Focusing on the influence of lifestyle factors on prognosis und quality of life (QOL), a comprehensive literature search of clinical studies published mainly in the years 2000 until 2015 was performed and the current knowledge based on these clinical studies reviewed. Besides avoiding risk factors (such as smoking and overindulgence in alcohol), healthy weight, regular and moderate PA as well
Treatment of MetastaticColorectalCancer: Standard of Care and Future Perspectives 27493945 2016 08 05 2018 11 13 2297-4725 32 3 2016 Jun Visceral medicine Visc Med Treatment of MetastaticColorectalCancer: Standard of Care and Future Perspectives. 178-83 10.1159/000446052 Palliative chemotherapy for metastaticcolorectalcancer has undergone substantial changes in recent years. The implementation of modern biologicals in the treatment has substantially improved overall survival up to 30 (...) to a survival of 9-12 months. Prospective trials evaluating an optimal approach to this subgroup are still missing. First results from strategies targeting the aberrant signal transduction are promising and require further validation. Despite the advances so far, life expectancy unfortunately continues to be limited in the majority of patients with metastaticcolorectalcancer. New strategies are needed to improve the prognosis. To this end, the identification of Her2/neu as a potential target and first
Tumor necrosis factor-Î± (TNF-Î±)-308G/A promoter polymorphism in colorectalcancer in ethnic Kashmiri population â€” A case control study in a detailed perspective 27331018 2016 06 22 2018 11 13 2214-5400 9 2016 Sep Meta gene Meta Gene Tumor necrosis factor-α (TNF-α)-308G/A promoter polymorphism in colorectalcancer in ethnic Kashmiri population - A case control study in a detailed perspective. 128-36 10.1016/j.mgene.2016.06.001 Inflammation constitutes one of the important components (...) of colorectalcancer (CRC) pathogenesis. Tumor necrosis factor-α (TNF-α), a cytokine and an important inflammatory mediator plays a pivotal role in the malignant cellular proliferation, angiogenesis, tissue invasion and metastasis in CRC. The studies on association of various polymorphisms in human TNF-α gene including TNF-α-308G/A single nucleotide polymorphism (SNP) are limited, mixed and inconclusive. The aim of this study was to analyze the association of TNF-α-308G/A promoter SNP with colorectalcancer
The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable ColorectalCancer 27070934 2016 07 21 2017 02 24 1528-1140 265 3 2017 Mar Annals of surgery Ann. Surg. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable ColorectalCancer. 539-546 10.1097/SLA.0000000000001743 The study aims to investigate the prognostic value of the lymphocyte (...) -to-monocyte ratio (LMR) in patients with colorectalcancer (CRC) undergoing curative resection and to compare it to established biomarkers including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), modified Glasgow prognostic score (mGPS), and combined BRAF-mismatch repair (MMR) status. The prognostic significance of systemic inflammatory markers in CRC such as the NLR, PLR, and mGPS has been well defined. Commonly used genetic markers such as combined BRAF-MMR status have
Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in ColorectalCancer 27138577 2016 06 10 2016 06 10 1527-7755 34 18 2016 Jun 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in ColorectalCancer. 2157-64 10.1200/JCO.2015.65.9128 To develop and validate a radiomics nomogram (...) for preoperative prediction of lymph node (LN) metastasis in patients with colorectalcancer (CRC). The prediction model was developed in a primary cohort that consisted of 326 patients with clinicopathologically confirmed CRC, and data was gathered from January 2007 to April 2010. Radiomic features were extracted from portal venous-phase computed tomography (CT) of CRC. Lasso regression model was used for data dimension reduction, feature selection, and radiomics signature building. Multivariable logistic
Response to Cetuximab With or Without Irinotecan in Patients With Refractory MetastaticColorectalCancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study 27114605 2016 06 23 2016 06 23 1527-7755 34 19 2016 Jul 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Response to Cetuximab With or Without Irinotecan in Patients With Refractory MetastaticColorectalCancer Harboring the KRAS G13D (...) Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. 2258-64 10.1200/JCO.2015.65.6843 RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastaticcolorectalcancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors harboring the exon 2 KRAS G13D mutation may benefit from cetuximab. We aimed to assess cetuximab monotherapy and cetuximab plus irinotecan in patients